Ipamorelin

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue and GHS-R1a agonist, developed to investigate whether growth hormone secretion could be stimulated with greater endocrine selectivity than earlier compounds. It differs from GHRP-2 and GHRP-6 in its comparatively limited ACTH and cortisol responses in preclinical models. FAB Research supplies Ipamorelin as a standalone 10mg research pen — distinct from combination blends — for laboratory investigations examining growth hormone receptor pharmacology and pituitary function.

Ipamorelin activates GHS-R1a through G-protein-mediated signalling, initiating pathways associated with growth hormone release. A key research characteristic is its selective profile: a 1998 study demonstrated substantial growth hormone-releasing activity without significantly increasing ACTH or cortisol — contrasting with GHRP-2 and GHRP-6. Appetite effects are comparatively limited relative to GHRP-6. The compound provides a model for studying selective ghrelin receptor activation and distinguishing receptor pharmacology from broader endocrine responses.

The selectivity literature established Ipamorelin as a benchmark for selective growth hormone secretagogue research. Preclinical work characterised the endocrine profile relative to earlier compounds. Gastrointestinal motility research examined ghrelin receptor activity in gastric emptying models. Combination pharmacology with GHRH analogues demonstrated synergistic release. The standalone pen enables investigation of Ipamorelin's individual receptor profile separate from blend preparations. Note: listed by anti-doping authorities.

• 2.5 mg per application (one metered dose)
• 4 doses per pen (10 mg total)
• Selective GHS-R1a pentapeptide — reference compound for ghrelin receptor selectivity research
• Pre-filled sterile solution — no reconstitution step required

Storage: Store refrigerated at 2–8 °C in the original sealed box. Do not freeze. Protect from light.

• For in-vitro laboratory and preclinical research only — not for human or animal administration
• Listed by WADA — detection methods are established
• Selectivity profile established in 1998 (Raun et al.) — Ipamorelin was the first ghrelin receptor agonist shown to stimulate GH release with minimal cortisol and prolactin co-stimulation; this profile makes it preferred for studies isolating GH-axis effects from HPA axis co-activation
• Preferred secretagogue when cortisol and prolactin elevation must be minimised in the experimental design

• Research and clinical data: headache, water retention (consistent with GH axis activation)
• Notably low cortisol and prolactin elevation compared with GHRP-2, GHRP-6 and other ghrelin receptor agonists — selectivity established in peer-reviewed 1998 study
• Minimal appetite stimulation relative to GHRP-6
• Injection site reactions (transient)
• Anti-doping listed: detection established

Effects listed are observations from published research literature and are not predictions for any specific use. All FAB Research products are for in-vitro laboratory research — not for human or animal administration.